Country: Ավստրալիա
language: անգլերեն
source: APVMA (Australian Pesticides and Veterinary Medicines Authority)
AMOXYCILLIN AS AMOXYCILLIN TRIHYDRATE; CLAVULANIC ACID AS POTASSIUM CLAVULANATE
ZOETIS AUSTRALIA PTY LTD
clavulanic acid as K salt(100mg/Tb) + others
ORAL TABLET
AMOXYCILLIN AS AMOXYCILLIN TRIHYDRATE ANTIBIOTIC Active 400.0 mg/Tb; CLAVULANIC ACID AS POTASSIUM CLAVULANATE ANTIBIOTIC Active 100.0 mg/Tb
100 Tablets
VM - Veterinary Medicine
CALF | DOG | BEEF CALF | BITCH | BOVINE | CALF - PODDY | CALF - PREWEANING | CALF - SUCKER | CASTRATE | DAIRY CALF | NEONATAL CA
ANTIBIOTIC & RELATED
ANTIBIOTICS - ORAL, PARENTERAL | BACTERIAL INFECTION | AIRSACCULITIS | AMOXYCILLIN SENSITIVE BACTERIA | ANAEROBIC BACTERIAL INFECTION | ASSOCIATED WITH VIRAL DISEASE | AVIAN MYCOPLASMAS | CLAVULANIC ACID SENSITIVE | COCCIDIOSIS | CORYZA | CRD | DERMATOSES | DIARRHOEA | ENDOMETRITIS | ENTERITIS | ENZOOTIC PNEUMONIA | ESCHERICHIA COLI | EUROPEAN BROOD DISEASE | GENTAMICIN SENSITIVE | GRAM NEGATIVE ORGANISMS | GRAM POSITIVE ORGANISMS | HYPERMOTILITY | INFECTED WOUNDS | INFECTIONS | LACTATING | MASTITIS | POST PARTURIENT BACTERIAL INFE | PRIMARY BACTERIAL INFECTION | PROTOZOAL INFECTIONS | PYOMETRA | SALMONELLOSIS | SINUSITIS | SULFADIAZINE SENSITIVE BACTERI | SYSTEMIC BACTERIAL INFECTION | TRIMETHOPRIM SENSITIVE BACTERI | TYLOSIN SENSITIVE BACTERIA
Poison schedule: 4; Withholding period: MEAT: CALVES - DO NOT USE less than 4 da ys before slaughter for human consumptio n. Any variation by the prescribing v eterinarian to the approved dose, freque ncy, duration, route, disease or target species may result in the need to extend the approved withholding period. ESI : EXPORT SLAUGHTER INTERVAL (ESI): An ES I has not been established for this prod uct. Note – observing the meat withhold ing period may not be sufficient to miti gate potential risks to export trade. Tr ade advice should be sought from Jurox P ty Limited on 1800 023 312 before using this product.; Host/pest details: CALF: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; DOG: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; Poison schedule: 4; Withholding period: WHP: CALVES: DO NOT USE LESS THAN 4 D AYS BEFORE SLAUGHTER FOR HUMAN CONSUMPT ION. DO NOT USE IN BOBBY CALVES. EXPOR T SLAUGHTER INTERVAL (ESI): This produc t does not have an ESI established. Fo r advice on the ESI, contact Jurox Pty Limited on 1800 023 312 before using th is product.; Host/pest details: CALF: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; DOG: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; For the treatment of bacterial infections sensitive to clavulanic acid and amoxicillin in calves and dogs.For oral administration only. DO NOT administer to small herbivores (e.g. guinea pig) or animals with a history of allergic reactions to penicillins. DO NOT USE in bobby calves. Not indicated for cases involving Pseudomonas spp.
Registered
2023-07-01
JUROCLAV 500 BROAD SPECTRUM ANTIBIOTIC TABLETS 61671/136334 Product Name: APVMA Approval No: Label Name: JUROCLAV 500 BROAD SPECTRUM ANTIBIOTIC TABLETS Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Constituent Statements: Each tablet contains 400 mg AMOXYCILLIN as amoxycillin trihydrate and 100 mg CLAVULANIC ACID as potassium clavulanate. Claims: For the treatment of bacterial infections sensitive to clavulanic acid and amoxicyllin in calves and dogs. Juroclav 500 Broad Spectrum Antibiotic Tablets have a notably broad spectrum of bactericidal activity against bacteria commonly found in calves and dogs and are indicated for the oral treatment of bacterial infections caused by susceptible organisms. These include enteritis, respiratory tract infections, and skin infections in dogs. PRODUCT SUMMARY • Dual action of clavulanic acid and amoxycillin. • Extended spectrum of activity - clavulanate extends the spectrum of amoxycillin by making it active against resistant (B-lactamase producing) strains of Staphylococcus spp., E. coli and Salmonella spp., as well as adding Klebsiella spp. to the list of susceptible organisms. • Rapid bactericidal action - increases the likelihood of a rapid clinical cure. • Excellent absorption and penetration. • Easy to administer. • Convenient twice daily dosage. • Absorption not significantly affected by food. MODE OF ACTION Resistance to many antibiotics is caused by B-lactamase enzymes which destroy the antibiotic before it can act on the bacteria. The clavulanate in Juroclav counteracts this defence mechanism by inactivating the B-lactamases, thus rendering the organisms sensitive to amoxycillin's rapid bactericidal effect at concentrations readily attainable in the body. In vitro Juroclav is active against a wide range of clinically important bacteria, including: Gram - positive Staphylococcus spp (including B-lactamase producing strains); Corynebacterium spp.; Streptococcus spp. RLP APPROVED Gram - negative Escheri read_full_document
JUROCLAV TABLETS Page 1 of 6 continued ISSUED: 19 NOVEMBER 2012 SAFETY DATA SHEET SECTION 1: IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY PRODUCT NAME: JUROCLAV BROAD SPECTRUM ANTIBIOTIC TABLETS PRODUCT CODE: 503585 (50 mg x 100’s); 503590 (250 mg x 250’s); 503595 (500 mg x 100’s) RECOMMENDED USE: For the treatment of bacterial infections sensitive to clavulanic acid and amoxicillin in dogs, cats and calves. COMPANY IDENTIFICATION: Jurox Pty Limited ADDRESS: 85 Gardiner Street Rutherford NSW 2320 Australia CUSTOMER CENTRE: 1800 023 312 NATIONAL POISONS INFORMATION CENTRE: 131126 (Australia-wide) EMERGENCY TELEPHONE NUMBER: 1800 023 312 (9a.m. – 5p.m.) SECTION 2: HAZARDS IDENTIFICATION GHS HAZARD CLASSIFICATIONS: EYE IRRITATION CATEGORY 2A RESPIRATORY SENSITIZER CATEGORY 1 SKIN CORROSION/IRRITATION CATEGORY 2 SKIN SENSITISER CATEGORY 1 STOT-SE CATEGORY 3 GHS PICTOGRAMS*: EXCLAMATION MARK HEALTH HAZARD SIGNAL WORD*: DANGER HAZARD STATEMENTS*: Causes skin irritation. Many cause an allergic skin reaction. Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause respiratory irritation. PRECAUTIONARY STATEMENTS*: PREVENTION Avoid breathing dust. Wash hands thoroughly after handling. Use only outdoors or in a well-ventilated area. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves. Use personal protective equipment as required. In case of inadequate ventilation wear respiratory protection. RESPONSE IF ON SKIN: Wash with plenty of soap and water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Call a POISON CENTRE or doctor if you feel unwell. If skin irritation or rash occurs: Get medical advice. If eye irritation persists: Get medical advice. JUROCLAV TABLETS Page 2 of 6 continued If experiencing respiratory symptoms: Call a POISON CE read_full_document
WWW.JUROX.COM.AU Customer Service 1800 023 312 ® Registered Trademark of Jurox Pty Limited TECHNICAL NOTES ACTIVE CONSTITUENTS Each tablet of Juroclav 50, Juroclav 250 or Juroclav 500 contains both clavulanic acid (as clavulanate potassium) 10 mg, 50 mg or 100 mg; and amoxicillin (as amoxicillin trihydrate) 40 mg, 200 mg or 400 mg. ACTIONS Resistance to many antibiotics is caused by β-lactamase enzymes which destroy the antibiotic before it can act on the bacteria. The clavulanate in Juroclav counteracts this defence mechanism by inactivating the β-lactamases, thus rendering the organisms sensitive to amoxicillin’s rapid bactericidal effect at concentrations readily attainable in the body. MICROBIOLOGY In vitro, Juroclav is active against a wide range of clinically important bacteria, including:- • GRAM-POSITIVE BACTERIA: _Staphylococcus _spp. (including β-lactamase producing strains), _Corynebacterium_ spp. and _Streptococcus_ spp.; • GRAM-NEGATIVE BACTERIA: _Escherichia coli _(including β-lactamase producing strains), _Salmonella_ spp. (including β-lactamase producing strains), _Bordetella bronchiseptica_, _Pasteurella _spp_., Proteus mirabilis_ and other sensitive strains and _Klebsiella _spp. Juroclav is not indicated for cases involving _Pseudomonas_ spp. INDICATIONS JUROCLAV 50 AND 250 TABLETS: Clinically, Juroclav has been shown to be effective in treating a wide range of diseases of cats and dogs, including skin disease (deep and superficial pyodermas), urinary tract infection, respiratory disease (involving upper and lower respiratory tract) and enteritis. They have a notably broad spectrum of bactericidal activity against bacteria commonly found in cats and dogs, and are indicated for the oral treatment of bacterial infections caused by susceptible organisms. JUROCLAV 500 TABLETS: Have a notably broad spectrum of bactericidal activity against bacteria commonly found in calves and dogs and are indicated for the oral treatment of bacterial infections caused by susceptible organisms. These incl read_full_document